Singlomics Appoints Dr. Qian Shi as Chief Executive Officer (CEO)
"Focusing on the highly unmet clinical needs of treating infectious diseases and cancers, developing effective and affordable medicine for the people of China"
On August 1, 2021, Singlomics Biopharmaceuticals Co., Ltd., a R&D company committed to using single-cell sequencing technology platforms to research and develop antibody drugs, and to promoting the discovery of innovative medicine for the treatment of infectious as well as autoimmune diseases and cancers, announced the appointment of Dr. Qian Shi as company CEO. Dr. Shi will be fully responsible for managing all departments of the company.
Dr. Shi Qian
Prior to joining Singlomics, Dr. Shi was the General Manager and Head of Scientific Research of the Chinese arm of Apollomics Inc. Under his leadership, his team accomplished the submission of two INDs for the treatment of acute myeloid leukemia (a Phase III study) and solid tumors (a Phase I study), respectively, enabling the company to enter clinical stage. Before his appointment at Apollomics, he worked for more than seven years at Crown Bioscience Inc., as the General Manager of Taicang branch and Vice President of Oncology, directing the Department of In vitro & In vivo Tumor Pharmacology.
Dr. Shi has served as a professor and principal investigator at Fudan University, Shanghai. He had also worked as a scientist at ArQule Inc. in the United States. He earned his PhD in Oncology and Cancer Biology from the University of Texas MD Anderson Cancer Center, and undertook postdoctoral training at the Dana-Farber Cancer Institute, Harvard Medical School. He has Bachelor's and Master's degrees in Genetics from Fudan University.
Academician Xiaoliang Xie from Peking University, founder of Singlomics, said: "We are very pleased that Singlomics can hire Dr. Shi, such a talented manager with extensive experience and a background in academia, CRO services, drug discovery and clinical development. We believe he will bring a powerful momentum to accelerate the clinical development of our existing SARS-CoV-2 antibody products, broaden our product pipelines, and bring advanced technological achievements to market."
Dr Shi Qian said: "It is a great honor to join Singlomics. With its renown founder, Dr. Xiaoliang Xie, and the full range of supports from well-known investors such as GL Ventures and Huagai Healthcare, as well as the Beijing Municipal and Changping District Governments, I believe Singlomics has had an excellent head-start. The company possesses a unique and innovative single-cell antibody drug discovery platform which can accelerate the R&D of medicines for treating infectious diseases and cancers. The company is poised to bring effective and affordable medicine to the people of China.”
About Singlomics
Singlomics Biopharmaceuticals Co., Ltd., registered in June 2020, is a biotechnology company led by Dr. Xiaoliang Xie, an internationally renowned biophysical chemist and member of four National Academies in both China and US. Singlomics is committed to using single-cell sequencing technology platforms to research and develop antibody drugs, and to promoting the discovery of innovative medicine for the treatment of infectious and autoimmune diseases. The members of the core scientific team all graduated from Harvard University, Peking University and other prestigious universities, and have substantial experience in single-cell genomics, transcriptomics, methylomics, immunology, etc.
Singlomics has completed the first round of financing from China's medical and health investors, and is preparing to build an antibody drug production base in the Changping District of Beijing with a focus on expanding the company’s product portfolio and enhancing manufacturing capability. DXP593 and DXP604, two current products of the company, are monoclonal antibodies with potent neutralizing ability against concerning Covid variants. They were screened from convalescent COVID-19 patients by using the company’s state-of-the-art single-cell sequencing technology platform. Both are currently under clinical development for the treatment and prevention of COVID-19.
Singlomics Contact:
Ms. Zeng
Email:contact@singlomics.com
Tel: +86-10-80765087
